BASEL, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) announced today that its placebo-controlled pivotal phase III BACH trial (Benefit of Alitretinoin in Chronic Hand dermatitis) successfully met its primary objective. Alitretinoin was effective in patients suffering from severe and refractory chronic hand dermatitis, as determined by the stringent endpoint of clear and almost clear hands. Currently, no approved treatment exists for this debilitating disease which prevents patients from using their hands normally. These positive data will form the basis of regulatory submissions later this year.
